Long Term Efficacy and Safety of Dupilumab for Eosinophilic Esophagitis

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swathi Eluri, MD, MS discuss “Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial,” by Summarizing Rothenber M, Dellon E, Collins M, et al. Lancet Gastroenterol Hep. 2023; 9: 990-1004

Om Podcasten

A new monthly publication from the American College of Gastroenterology, Evidence-Based GI (EBGI) uses evidence-based methods to create abstracts and explain study results of new and important articles in the field of gastroenterology and hepatology. Listen as editors of EBGI discuss the articles they review and how the recommendations can be applied to your practice.